In the CORE-TIMI 72a and CORE2-TIMI 72b phase 3 trials involving patients with severe hypertriglyceridemia, olezarsen led to a significantly greater reduction in the triglyceride level and in acute pancreatitis events than placebo. Full results: nej.md/491XG5V
#AHA25
#AHA25
November 8, 2025 at 2:45 PM
In the CORE-TIMI 72a and CORE2-TIMI 72b phase 3 trials involving patients with severe hypertriglyceridemia, olezarsen led to a significantly greater reduction in the triglyceride level and in acute pancreatitis events than placebo. Full results: nej.md/491XG5V
#AHA25
#AHA25
In which scenario is utilizing a factor Xa inhibitor instead of a Partial Thromboplastin Time (PTT)-driven heparin protocol appropriate?
When a patient has…
A. Afib on rivaroxaban at home
B. Hyperbilirubinemia
C. Hypertriglyceridemia
D. Lupus erythematosus
The answer is in the thread
When a patient has…
A. Afib on rivaroxaban at home
B. Hyperbilirubinemia
C. Hypertriglyceridemia
D. Lupus erythematosus
The answer is in the thread
November 4, 2025 at 2:07 PM
In which scenario is utilizing a factor Xa inhibitor instead of a Partial Thromboplastin Time (PTT)-driven heparin protocol appropriate?
When a patient has…
A. Afib on rivaroxaban at home
B. Hyperbilirubinemia
C. Hypertriglyceridemia
D. Lupus erythematosus
The answer is in the thread
When a patient has…
A. Afib on rivaroxaban at home
B. Hyperbilirubinemia
C. Hypertriglyceridemia
D. Lupus erythematosus
The answer is in the thread
New in the October 2, 2025, issue of NEJM:
Intravenous Rehydration for Severe Acute Malnutrition (GASTROSAM trial) nej.md/3TjfSP7
Medical Imaging and Pediatric Hematologic Cancer Risk nej.md/41YXEHD
Olezarsen in Moderate Hypertriglyceridemia (Essence–TIMI 73b phase 3 trial) nej.md/4mws7Vt
Intravenous Rehydration for Severe Acute Malnutrition (GASTROSAM trial) nej.md/3TjfSP7
Medical Imaging and Pediatric Hematologic Cancer Risk nej.md/41YXEHD
Olezarsen in Moderate Hypertriglyceridemia (Essence–TIMI 73b phase 3 trial) nej.md/4mws7Vt
October 2, 2025 at 1:03 PM
New in the October 2, 2025, issue of NEJM:
Intravenous Rehydration for Severe Acute Malnutrition (GASTROSAM trial) nej.md/3TjfSP7
Medical Imaging and Pediatric Hematologic Cancer Risk nej.md/41YXEHD
Olezarsen in Moderate Hypertriglyceridemia (Essence–TIMI 73b phase 3 trial) nej.md/4mws7Vt
Intravenous Rehydration for Severe Acute Malnutrition (GASTROSAM trial) nej.md/3TjfSP7
Medical Imaging and Pediatric Hematologic Cancer Risk nej.md/41YXEHD
Olezarsen in Moderate Hypertriglyceridemia (Essence–TIMI 73b phase 3 trial) nej.md/4mws7Vt
In another home-run for genetics-enabled drug development, APOC3 inhibition is approved to treat a disease of hypertriglyceridemia.
👇
www.science.org/doi/10.1126/....
Human genetics identified the target in 2008, thanks to work done in the Amish population.
👇
www.nature.com/articles/s41...
👇
www.science.org/doi/10.1126/....
Human genetics identified the target in 2008, thanks to work done in the Amish population.
👇
www.nature.com/articles/s41...
A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection
Apolipoprotein C-III (apoC-III) inhibits triglyceride hydrolysis and has been implicated in coronary artery disease. Through a genome-wide association study, we have found that about 5% of the Lancast...
www.science.org
January 21, 2025 at 12:14 AM
In another home-run for genetics-enabled drug development, APOC3 inhibition is approved to treat a disease of hypertriglyceridemia.
👇
www.science.org/doi/10.1126/....
Human genetics identified the target in 2008, thanks to work done in the Amish population.
👇
www.nature.com/articles/s41...
👇
www.science.org/doi/10.1126/....
Human genetics identified the target in 2008, thanks to work done in the Amish population.
👇
www.nature.com/articles/s41...
Rona gets FDA go-ahead for Phase 2 siRNA heart disease trial
Company to initiate clinical study of gene-silencing drug targeting hypertriglyceridemia via a reduction in APOC3 protein expression.
#longevity #biotech #RNA #heartdisease
Company to initiate clinical study of gene-silencing drug targeting hypertriglyceridemia via a reduction in APOC3 protein expression.
#longevity #biotech #RNA #heartdisease
Rona gets FDA go-ahead for Phase 2 siRNA heart disease trial
Company to initiate clinical study of gene-silencing drug targeting hypertriglyceridemia via a reduction in APOC3 protein expression.
longevity.technology
March 19, 2025 at 6:06 PM
Rona gets FDA go-ahead for Phase 2 siRNA heart disease trial
Company to initiate clinical study of gene-silencing drug targeting hypertriglyceridemia via a reduction in APOC3 protein expression.
#longevity #biotech #RNA #heartdisease
Company to initiate clinical study of gene-silencing drug targeting hypertriglyceridemia via a reduction in APOC3 protein expression.
#longevity #biotech #RNA #heartdisease
#Hypertriglyceridemia‐modulated gut #microbiota promotes lysophosphatidylcholine generation to aggravate acute pancreatitis in a TLR4‐dependent manner onlinelibrary.wiley.com/doi/full/10....
#microbiome #GutHealth #inflammation #immune #FMT
#microbiome #GutHealth #inflammation #immune #FMT
Hypertriglyceridemia‐modulated gut microbiota promotes lysophosphatidylcholine generation to aggravate acute pancreatitis in a TLR4‐dependent manner
Hypertriglyceridemia (HTG) can lead to the disorder of gut microbiota in mice, resulting in the increase of endotoxin content. HTG can also aggravate the damage of intestinal barrier function and int....
onlinelibrary.wiley.com
February 12, 2025 at 7:56 AM
#Hypertriglyceridemia‐modulated gut #microbiota promotes lysophosphatidylcholine generation to aggravate acute pancreatitis in a TLR4‐dependent manner onlinelibrary.wiley.com/doi/full/10....
#microbiome #GutHealth #inflammation #immune #FMT
#microbiome #GutHealth #inflammation #immune #FMT
Free Webinar – July 1 at 12PM ET
Join Dr. Seth J. Baum + Dr. James A. Underberg to gain insights into diagnosing + managing Severe Hypertriglyceridemia
🧠 Insightful. 🔍 Practical. 💬 Live Q&A.
📍 Register: nta.ampstream.io/nta1
@nattgalliance.bsky.social
#SevereHTG #Hypertriglyceridemia #CardioSky
Join Dr. Seth J. Baum + Dr. James A. Underberg to gain insights into diagnosing + managing Severe Hypertriglyceridemia
🧠 Insightful. 🔍 Practical. 💬 Live Q&A.
📍 Register: nta.ampstream.io/nta1
@nattgalliance.bsky.social
#SevereHTG #Hypertriglyceridemia #CardioSky
June 16, 2025 at 5:29 PM
Free Webinar – July 1 at 12PM ET
Join Dr. Seth J. Baum + Dr. James A. Underberg to gain insights into diagnosing + managing Severe Hypertriglyceridemia
🧠 Insightful. 🔍 Practical. 💬 Live Q&A.
📍 Register: nta.ampstream.io/nta1
@nattgalliance.bsky.social
#SevereHTG #Hypertriglyceridemia #CardioSky
Join Dr. Seth J. Baum + Dr. James A. Underberg to gain insights into diagnosing + managing Severe Hypertriglyceridemia
🧠 Insightful. 🔍 Practical. 💬 Live Q&A.
📍 Register: nta.ampstream.io/nta1
@nattgalliance.bsky.social
#SevereHTG #Hypertriglyceridemia #CardioSky
Sobi’s Olezarsen Shows Promising Results for Treating Severe Hypertriglyceridemia#Sweden#Stockholm#Sobi#Olezarsen#sHTG
Sobi’s Olezarsen Shows Promising Results for Treating Severe Hypertriglyceridemia
A pivotal study of olezarsen presented at the AHA reveals significant benefits in treating severe hypertriglyceridemia, notably reducing acute pancreatitis events.
third-news.com
November 8, 2025 at 3:45 PM
Sobi’s Olezarsen Shows Promising Results for Treating Severe Hypertriglyceridemia#Sweden#Stockholm#Sobi#Olezarsen#sHTG
📃Scientific paper: Incidence and risk factors of hypertriglyceridemia in males with human immunodeficiency virus who ar...
➡️ Continued on ES/IODE
➡️ Continued on ES/IODE
July 30, 2024 at 7:15 AM
📃Scientific paper: Incidence and risk factors of hypertriglyceridemia in males with human immunodeficiency virus who ar...
➡️ Continued on ES/IODE
➡️ Continued on ES/IODE
Hemophagocytic Lymphohistiocytosis
🔹Life-threatening syndrome of overwhelming inflammation
🔹Is crucial to search and treat the underlying trigger
🚩Fever, #Splenomegaly, #Cytopenia, #hyperferritinemia, #hypertriglyceridemia, bone marrow #hemophagocytosis
#HLH
@nejm.org
www.nejm.org/doi/pdf/10.1...
🔹Life-threatening syndrome of overwhelming inflammation
🔹Is crucial to search and treat the underlying trigger
🚩Fever, #Splenomegaly, #Cytopenia, #hyperferritinemia, #hypertriglyceridemia, bone marrow #hemophagocytosis
#HLH
@nejm.org
www.nejm.org/doi/pdf/10.1...
Hemophagocytic Lymphohistiocytosis | NEJM
HLH, a cytokine-mediated hyperinflammation syndrome, causes fever, pancytopenia, and
hemophagocytosis and is often fatal. Antiinflammatory agents, etoposide, and interferon-γ
antibody are the main ...
www.nejm.org
February 6, 2025 at 8:03 AM
Hemophagocytic Lymphohistiocytosis
🔹Life-threatening syndrome of overwhelming inflammation
🔹Is crucial to search and treat the underlying trigger
🚩Fever, #Splenomegaly, #Cytopenia, #hyperferritinemia, #hypertriglyceridemia, bone marrow #hemophagocytosis
#HLH
@nejm.org
www.nejm.org/doi/pdf/10.1...
🔹Life-threatening syndrome of overwhelming inflammation
🔹Is crucial to search and treat the underlying trigger
🚩Fever, #Splenomegaly, #Cytopenia, #hyperferritinemia, #hypertriglyceridemia, bone marrow #hemophagocytosis
#HLH
@nejm.org
www.nejm.org/doi/pdf/10.1...
🚨 Don’t miss this must-attend webinar!
🎯 Innovations in Severe Hypertriglyceridemia Management & Cardioprotection
🎙️ Keynote: Prof. Daniel Gaudet
📅 Wednesday, June 4, 2025
🕕 17:00 CET
💻 Online | Registration required
🔗 Reserve your spot now!
Registration link below!
🎯 Innovations in Severe Hypertriglyceridemia Management & Cardioprotection
🎙️ Keynote: Prof. Daniel Gaudet
📅 Wednesday, June 4, 2025
🕕 17:00 CET
💻 Online | Registration required
🔗 Reserve your spot now!
Registration link below!
June 2, 2025 at 7:04 PM
🚨 Don’t miss this must-attend webinar!
🎯 Innovations in Severe Hypertriglyceridemia Management & Cardioprotection
🎙️ Keynote: Prof. Daniel Gaudet
📅 Wednesday, June 4, 2025
🕕 17:00 CET
💻 Online | Registration required
🔗 Reserve your spot now!
Registration link below!
🎯 Innovations in Severe Hypertriglyceridemia Management & Cardioprotection
🎙️ Keynote: Prof. Daniel Gaudet
📅 Wednesday, June 4, 2025
🕕 17:00 CET
💻 Online | Registration required
🔗 Reserve your spot now!
Registration link below!
Thoughts on this? >> Arrowhead Subsidiary Visirna Sells Rights to
Hypertriglyceridemia Candidate Plozasiran in Greater China to
Sanofi >> Comment below! #healthtech #mhealth #industry40 #IoT #AI
Hypertriglyceridemia Candidate Plozasiran in Greater China to
Sanofi >> Comment below! #healthtech #mhealth #industry40 #IoT #AI
Arrowhead Subsidiary Visirna Sells Rights to
Hypertriglyceridemia Candidate Plozasiran in Greater China to
Sanofi
– Sanofi to pay $130 million upfront and up to $265 million in potential regulatory milestones to Visirna Therapeutics, a majority-owned subsidiary of Arrowhead, which was previously granted rights to investigational plozasiran in Greater China – Sanofi will receive an exclusive license to develop and commercialize investigational plozasiran in Greater China from Visirna Therapeutics, offering …
dlvr.it
August 1, 2025 at 11:05 AM
Thoughts on this? >> Arrowhead Subsidiary Visirna Sells Rights to
Hypertriglyceridemia Candidate Plozasiran in Greater China to
Sanofi >> Comment below! #healthtech #mhealth #industry40 #IoT #AI
Hypertriglyceridemia Candidate Plozasiran in Greater China to
Sanofi >> Comment below! #healthtech #mhealth #industry40 #IoT #AI
the safety information that comes with vials is akin to the safety information that comes with pills
the FAQ list of dozens of things people actually worry about with injections has no equivalent for pills. no one frantically posts "I just took a pill, is it going to give me hypertriglyceridemia?!"
the FAQ list of dozens of things people actually worry about with injections has no equivalent for pills. no one frantically posts "I just took a pill, is it going to give me hypertriglyceridemia?!"
October 26, 2025 at 12:21 AM
the safety information that comes with vials is akin to the safety information that comes with pills
the FAQ list of dozens of things people actually worry about with injections has no equivalent for pills. no one frantically posts "I just took a pill, is it going to give me hypertriglyceridemia?!"
the FAQ list of dozens of things people actually worry about with injections has no equivalent for pills. no one frantically posts "I just took a pill, is it going to give me hypertriglyceridemia?!"
Effects of #hypertriglyceridemia with or without NEFA elevation on β-cell function and #insulin clearance and sensitivity: new Featured study in #JCEM. #FreeToView
#T2D #FattyAcids #lipids #BetaCell #diabetes
@endocrinesociety.bsky.social
doi.org/10.1210/clin...
#T2D #FattyAcids #lipids #BetaCell #diabetes
@endocrinesociety.bsky.social
doi.org/10.1210/clin...
Effects of Hypertriglyceridemia With or Without NEFA Elevation on β-cell Function and Insulin Clearance and Sensitivity
AbstractContext. Hypertriglyceridemia is a risk factor for developing type 2 diabetes (T2D) and might contribute to its pathogenesis either directly or thr
doi.org
March 14, 2025 at 2:01 PM
Effects of #hypertriglyceridemia with or without NEFA elevation on β-cell function and #insulin clearance and sensitivity: new Featured study in #JCEM. #FreeToView
#T2D #FattyAcids #lipids #BetaCell #diabetes
@endocrinesociety.bsky.social
doi.org/10.1210/clin...
#T2D #FattyAcids #lipids #BetaCell #diabetes
@endocrinesociety.bsky.social
doi.org/10.1210/clin...
Hypertriglyceridemia as a Key Contributor to Abdominal Aortic Aneurysm Development and Rupture: Insights from Genetic and Experimental Models https://www.medrxiv.org/content/10.1101/2024.08.07.24311621v1
Hypertriglyceridemia as a Key Contributor to Abdominal Aortic Aneurysm Development and Rupture: Insights from Genetic and Experimental Models https://www.medrxiv.org/content/10.1101/2024.08.07.24311621v1
Abdominal aortic aneurysm (AAA) is a life-threatening vascular disease without effective medications
www.medrxiv.org
August 13, 2024 at 2:56 AM
Hypertriglyceridemia as a Key Contributor to Abdominal Aortic Aneurysm Development and Rupture: Insights from Genetic and Experimental Models https://www.medrxiv.org/content/10.1101/2024.08.07.24311621v1
Implementing the #ACMG/AMP guidelines is no simple task. Study offers a #pathogenicity assessment of genetic #variants found in patients with severe #hypertriglyceridemia, shedding light on the diagnosis of #familialchylomicronemiasyndrome bit.ly/3DKXbjk
March 14, 2025 at 7:44 PM
Implementing the #ACMG/AMP guidelines is no simple task. Study offers a #pathogenicity assessment of genetic #variants found in patients with severe #hypertriglyceridemia, shedding light on the diagnosis of #familialchylomicronemiasyndrome bit.ly/3DKXbjk
Rona Therapeutics Gets FDA Approval for Phase 2 Study of Innovative Hypertriglyceridemia Treatment#Shanghai#USA#FDA_Clearance#Rona_Therapeutics#RN0361
Rona Therapeutics Gets FDA Approval for Phase 2 Study of Innovative Hypertriglyceridemia Treatment
Rona Therapeutics has received FDA clearance to begin Phase 2 trials for RN0361, a targeted siRNA treatment for managing hypertriglyceridemia, aiming to improve patient outcomes.
third-news.com
March 17, 2025 at 11:14 AM
Rona Therapeutics Gets FDA Approval for Phase 2 Study of Innovative Hypertriglyceridemia Treatment#Shanghai#USA#FDA_Clearance#Rona_Therapeutics#RN0361
Treatment with olezarsen significantly reduced triglyceride levels at 6 months compared to placebo in pts w/ moderate hypertriglyceridemia & elevated CV risk, according to results of the Essence-TIMI 73b study presented during #ESCCongress. 🔗 More: https://bit.ly/4g4r50H
August 30, 2025 at 5:31 PM
Treatment with olezarsen significantly reduced triglyceride levels at 6 months compared to placebo in pts w/ moderate hypertriglyceridemia & elevated CV risk, according to results of the Essence-TIMI 73b study presented during #ESCCongress. 🔗 More: https://bit.ly/4g4r50H
Triglycerides and T Cells in Cardiovascular Risk: Inflammatory Transcriptomic Profile in Hypertriglyceridemia Patients' T Cells🔓
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
Triglycerides and T Cells in Cardiovascular Risk: Inflammatory Transcriptomic Profile in Hypertriglyceridemia Patients' T Cells
Triglycerides and T cells play a key role in atherosclerosis, the leading cause of cardiovascular disease (CVD). Moderately elevated triglycerides hav…
www.sciencedirect.com
September 22, 2025 at 6:30 PM
Triglycerides and T Cells in Cardiovascular Risk: Inflammatory Transcriptomic Profile in Hypertriglyceridemia Patients' T Cells🔓
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
It’s #TrigTriviaTuesday! 💥
Pancreatitis risk doesn’t wait—so here’s your quick quiz:
At what TG level does risk really spike?
A) >250 mg/dL
B) >500 mg/dL
C) >1,000 mg/dL
D) >2,000 mg/dL
Drop your guess & let’s talk TGs + pancreatitis ⬇️
#TrigTriviaTuesday #Hypertriglyceridemia #MedEd
Pancreatitis risk doesn’t wait—so here’s your quick quiz:
At what TG level does risk really spike?
A) >250 mg/dL
B) >500 mg/dL
C) >1,000 mg/dL
D) >2,000 mg/dL
Drop your guess & let’s talk TGs + pancreatitis ⬇️
#TrigTriviaTuesday #Hypertriglyceridemia #MedEd
August 5, 2025 at 6:59 PM
It’s #TrigTriviaTuesday! 💥
Pancreatitis risk doesn’t wait—so here’s your quick quiz:
At what TG level does risk really spike?
A) >250 mg/dL
B) >500 mg/dL
C) >1,000 mg/dL
D) >2,000 mg/dL
Drop your guess & let’s talk TGs + pancreatitis ⬇️
#TrigTriviaTuesday #Hypertriglyceridemia #MedEd
Pancreatitis risk doesn’t wait—so here’s your quick quiz:
At what TG level does risk really spike?
A) >250 mg/dL
B) >500 mg/dL
C) >1,000 mg/dL
D) >2,000 mg/dL
Drop your guess & let’s talk TGs + pancreatitis ⬇️
#TrigTriviaTuesday #Hypertriglyceridemia #MedEd
Hypertriglyceridemia (HTG) is a major cardiovascular risk factor. This study reveals that genetic influences on TG levels in AA populations are underexplored, limiting treatment opportunities. #Hypertriglyceridemia PMID:38559137, medRxiv 2024 https://doi.org/10.1101/2024.03.11.24304107
February 4, 2025 at 9:10 AM
Hypertriglyceridemia (HTG) is a major cardiovascular risk factor. This study reveals that genetic influences on TG levels in AA populations are underexplored, limiting treatment opportunities. #Hypertriglyceridemia PMID:38559137, medRxiv 2024 https://doi.org/10.1101/2024.03.11.24304107
These drugs should be first line for most people with obesity related hypertriglyceridemia. Supplementary appendix: 32% reduction. Bonkers.
November 14, 2024 at 1:03 PM
These drugs should be first line for most people with obesity related hypertriglyceridemia. Supplementary appendix: 32% reduction. Bonkers.
Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia | New England Journal of Medicine www.nejm.org/doi/full/10....
Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia | NEJM
Highly effective therapies to reduce triglyceride levels are lacking. Olezarsen is
an N-acetylgalactosamine–conjugated antisense oligonucleotide that targets the messenger
RNA of apolipoprotein C-I...
www.nejm.org
October 6, 2025 at 8:23 PM
Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia | New England Journal of Medicine www.nejm.org/doi/full/10....
Pseudo-hypertriglyceridemia in a 2-year-old male with global developmental delay, myopathy and adrenal hypoplasia: Publication date: Available online 20 February 2024
Source: Journal of Mass Spectrometry and Advances in the Clinical Lab
Author(s):… http://dlvr.it/T30R32 (JMSACL) #MassSpecRSS
Source: Journal of Mass Spectrometry and Advances in the Clinical Lab
Author(s):… http://dlvr.it/T30R32 (JMSACL) #MassSpecRSS
February 20, 2024 at 1:05 PM
Pseudo-hypertriglyceridemia in a 2-year-old male with global developmental delay, myopathy and adrenal hypoplasia: Publication date: Available online 20 February 2024
Source: Journal of Mass Spectrometry and Advances in the Clinical Lab
Author(s):… http://dlvr.it/T30R32 (JMSACL) #MassSpecRSS
Source: Journal of Mass Spectrometry and Advances in the Clinical Lab
Author(s):… http://dlvr.it/T30R32 (JMSACL) #MassSpecRSS
🤝Meet Domenico Tricò, past #EFSD Future Leaders Mentorship recipient whose work uncovered how hypertriglyceridemia drives #T2D in healthy individuals. A 2019 Rising Star too, he credits EFSD for shaping his career.
Read his paper📗 pubmed.ncbi.nlm.nih.gov/35760117/
Supported by AstraZeneca
#funding
Read his paper📗 pubmed.ncbi.nlm.nih.gov/35760117/
Supported by AstraZeneca
#funding
June 24, 2025 at 1:05 PM
🤝Meet Domenico Tricò, past #EFSD Future Leaders Mentorship recipient whose work uncovered how hypertriglyceridemia drives #T2D in healthy individuals. A 2019 Rising Star too, he credits EFSD for shaping his career.
Read his paper📗 pubmed.ncbi.nlm.nih.gov/35760117/
Supported by AstraZeneca
#funding
Read his paper📗 pubmed.ncbi.nlm.nih.gov/35760117/
Supported by AstraZeneca
#funding